share_log

海思科(002653.SZ):子公司HSK21542注射液新适应症上市许可申请获受理

Haisco Pharmaceutical Group (002653.SZ): Subsidiary HSK21542 injection new indication market approval application accepted.

Gelonghui Finance ·  Sep 23 05:05

On September 23, Gelonhui reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Liaoning Haisco Pharmaceutical Co., Ltd. received the "Acceptance Notice" issued by the National Medical Products Administration on September 23, 2024. The pharmaceutical name is HSK21542 Injection, indicated for moderate to severe pruritus related to chronic kidney disease in adult maintenance hemodialysis patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment